<DOC>
	<DOCNO>NCT00667082</DOCNO>
	<brief_summary>This clinical trial examine safety , pharmacokinetics , pharmacodynamics efficacy IV NPI-0052 ( proteasome inhibitor ) combination oral vorinostat ( Zolinza ; HDAC inhibitor ) patient non-small cell lung cancer , pancreatic cancer , melanoma lymphoma . Proteasome inhibitor block breakdown protein cell HDAC inhibitor block modification protein regulate gene expression cell . Both action preferentially affect cancer cell , combination two see great effect laboratory study .</brief_summary>
	<brief_title>NPI-0052 Vorinostat Patients With Non-small Cell Lung Cancer , Pancreatic Cancer , Melanoma Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>1 . Karnofsky Performance Status ( KPS ) 70 % . 2 . Nonsmall cell lung cancer , pancreatic adenocarcinoma , melanoma lymphoma standard , approve therapy available . Patients must lesions evaluable RECIST criterion . 3 . All Adverse Events prior chemotherapy , surgery , radiotherapy , must resolve CTCAE ( v. 3.0 ) Grade 1 less ( except hemoglobin ) . 4 . Adequate bone marrow , renal , liver function . 5 . Signed informed consent . 1 . Recent administration chemotherapy , biological , immunotherapy investigational agent , major surgery , radiotherapy . 2 . Intrathecal therapy . 3 . Known brain metastasis . 4 . Significant cardiac disease . 5 . Prior treatment vorinostat NPI0052 , HDACi ( include valproic acid ) proteasome inhibitor . 6 . Known allergy component vorinostat . Prior hypersensitivity reaction CTCAE Grade &gt; 3 therapy contain propylene glycol ethanol . 7 . Pregnant breastfeed woman . 8 . Concurrent , active secondary malignancy patient receive therapy . 9 . Significant active infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Non small Cell Lung Cancer</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>